Mavenclad: adverse event reports filed with FDA

6,763

reports as suspect product

0% of all reports · about 788 a year

1,128

reports, 12 months to June 2026

993 in the 12 months before

67.2%

marked serious by the reporter

90.3% across the class

2.4%

record death among outcomes, as reported

163 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Mavenclad reports recording the termmedian drug in purine antimetabolite

1. Fatiguetiredness10.7%722
2. Headachehead pain9.1%615
3. Lymphocyte count decreased6.8%459
4. Multiple sclerosis relapsea flare of multiple sclerosis5.6%382
5. Nauseafeeling sick5%340
6. White blood cell count decreasedlow white cell count4.9%329
7. Pneumonialung infection4.4%299
8. Urinary tract infectionbladder or urinary infection3.8%255
9. Multiple sclerosis3.3%225
10. Astheniaweakness or lack of energy2.8%188
11. Painpain, site not specified2.5%167
12. Dizzinesslight-headedness or unsteadiness2.4%161
13. Falla fall2.3%156
14. Lower respiratory tract infectiona chest infection2.3%153
15. Gait disturbancedifficulty walking2.2%150
16. Covid-19COVID-19 infection2.2%147
17. Lymphopenia2.1%142
18. Diarrhoealoose or frequent stools2.1%140
19. Nasopharyngitisa cold1.7%118
20. Alopeciahair loss1.7%114
21. Weight decreasedweight loss1.7%113
22. Malaisegeneral feeling of being unwell1.6%111
23. Feeling abnormalfeeling odd or not right1.6%108
24. Vomitingbeing sick1.6%107
25. Hypoaesthesianumbness1.6%105
26. Arthralgiajoint pain1.5%103
27. Alanine aminotransferase increasedraised liver enzyme (ALT)1.4%97
28. Pyrexiafever1.4%96
29. Back painback pain1.4%93
30. Deaththe patient died; cause not stated by this term1.3%91

Top 30 of 906 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 5 drugs in the purine antimetabolite class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 49,725 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 59.5% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 6,763 reports.

Drugs most often listed in the same reports

Other products listed in reports where Mavenclad is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the purine antimetabolite class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Mavenclad as a suspect or interacting product; reports listing it only as a concomitant medication (121) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.